SCHEMBL4291295

SCHEMBL4291295

O=C(Cc1ccc(F)cc1)c1ccc(O)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.54
HTT P42858 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
GRIN2B Q13224 4/20 0.52
MAPT P10636 2/20 0.51
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 2/20 0.51
TP53 P04637 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
ESR1 P03372 2/20 0.50
ESR2 Q92731 2/20 0.50
XBP1 P17861 1/20 0.48
HIF1A Q16665 1/20 0.48
GRIN1 Q05586 1/20 0.46
ACHE P22303 1/20 0.46
SNCA P37840 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SLC5A1 P13866 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27640786 0.89 KDM4E (0.58) LMNAHTTSMN1; SMN2GRIN2BMAPT
SCHEMBL6201900 0.82 RAB9A (0.59) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL5724883 0.79 RAB9A (0.68) LMNAHTTSMN1; SMN2GRIN2BMAPT
SCHEMBL8044730 0.78 LMNA (0.48) LMNAHTTMAPTKDM4EHSD17B10
SCHEMBL28440957 0.77 SNCA (0.50) LMNAGRIN2BKDM4EHSD17B10ESR1
SCHEMBL5231458 0.76 CES2 (0.55) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL5455143 0.75 KDM4E (0.49) LMNAGRIN2BKDM4EHSD17B10MAPK1
SCHEMBL7167952 0.75 SRD5A2 (0.62) LMNAHTTSMN1; SMN2MAPTNPC1
SCHEMBL4597302 0.75 MAPT (0.55) LMNAHTTSMN1; SMN2GRIN2BMAPT
SCHEMBL1701124 0.75 PTPN1 (0.57) LMNAGRIN2BKDM4EHSD17B10ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
WO-2007077961-A2 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands NR3C2, NR3C1, MC2R LMNA 2152/4885HTT 3165/4885SMN1; SMN2 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.